|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review显示文摘BACKGROUND Non-alcoholic fatty liver disease(NAFLD)is a common comorbidity with type 2 diabetes.The existing therapeutic options for NAFLD are not adequate.Hypocaloric diet and exercise is the cornerstone of therapy in NAFLD.Pioglitazone is the only drug recommended in diabetes patients with biopsy proven non-alcoholic steatohepatitis.The frequent coexistence of NAFLD and type 2 diabetes with their combined adverse health consequences and inadequate therapeutic options makes it necessary to search for newer alternatives.AIM To assess the effect of sodium glucose cotransporter-2(SGLT-2)inhibitors on liver enzymes in type 2 diabetes patients with NAFLD.METHODS We searched PubMed/MEDLINE,Cochrane library,Google scholar,and Clinicaltrials.gov for the relevant articles to be included in this systematic review.Human studies done in type 2 diabetes patients with NAFLD treated with SGLT-2 inhibitors for at least 12 wk were included.Data from eight studies(four randomised controlled trials and four observational studies)were extracted and a narrative synthesis was done.A total of 214 patients were treated with SGLT-2 inhibitors in these studies(94 in randomised controlled trials and 120 in observational studies).RESULTS The primary outcome measure was change in serum alanine aminotransferase level.Out of eight studies,seven studies showed a significant decrease in serum alanine aminotransferase level.Most of the studies revealed reduction in serum level of other liver enzymes like aspartate aminotransferase and gamma glutamyl transferase.Five studies that reported a change in hepatic fat exhibited a significant reduction in hepatic fat content in those treated with SGLT-2 inhibitors.Likewise,among the three studies that evaluated a change in indices of hepatic fibrosis,two studies revealed a significant improvement in liver fibrosis.Moreover,there was an improvement in obesity,insulin resistance,glycaemia,and lipid parameters in those subjects taking SGLT-2 inhibitors.The studies disclosed that about 17%(30/176)of the subjects taking SGLT-2 inhibitors developed adverse events and more than 40%(10/23)of them had genitourinary tract infections.CONCLUSION Based on low to moderate quality of evidence,SGLT-2 inhibitors improve the serum level of liver enzymes,decrease liver fat,and fibrosis with additional beneficial effects on various metabolic parameters in type 2 diabetes patients with NAFLD. | Henith Raj Harsh Durgia Rajan Palui Sadishkumar Kamalanathan Sandhiya Selvarajan Sitanshu Sekhar Kar Jayaprakash Sahoo | 2019 | World Journal of Diabetes2019，10，2： | 9 |
| 2 | Islet cell dysfunction in patients with chronic pancreatitis显示文摘Chronic pancreatitis(CP)is characterized by progressive inflammation and fibrosis of the pancreas that eventually leads to pancreatic exocrine and endocrine insufficiency.Diabetes in the background of CP is very difficult to manage due to high glycemic variability and concomitant malabsorption.Progressive beta cell loss leading to insulin deficiency is the cardinal mechanism underlying diabetes development in CP.Alpha cell dysfunction leading to deranged glucagon secretion has been described in different studies using a variety of stimuli in CP.However,the emerging evidence is varied probably because of dependence on the study procedure,the study population as well as on the stage of the disease.The mechanism behind islet cell dysfunction in CP is multifactorial.The intra-islet alpha and beta cell regulation of each other is often lost.Moreover,secretion of the incretin hormones such as glucagon like peptide-1 and glucose-dependent insulinotropic polypeptide is dysregulated.This significantly contributes to islet cell disturbances.Persistent and progressive inflammation with changes in the function of other cells such as islet delta cells and pancreatic polypeptide cells are also implicated in CP.In addition,the different surgical procedures performed in patients with CP and antihyperglycemic drugs used to treat diabetes associated with CP also affect islet cell function.Hence,different factors such as chronic inflammation,dysregulated incretin axis,surgical interventions and anti-diabetic drugs all affect islet cell function in patients with CP.Newer therapies targeting alpha cell function and beta cell regeneration would be useful in the management of pancreatic diabetes in the near future. | Ayan Roy Jayaprakash Sahoo Sadishkumar Kamalanathan Dukhabandhu Naik Pazhanivel Mohan Biju Pottakkat | 2020 | World Journal of Diabetes2020，11，7： | 5 |
| 3 | Diabetes and pancreatic cancer:Exploring the two-way traffic显示文摘Pancreatic cancer(PC)is often associated with a poor prognosis.Long-standing diabetes mellitus is considered as an important risk factor for its development.This risk can be modified by the use of certain antidiabetic medications.On the other hand,new-onset diabetes can signal towards an underlying PC in the elderly population.Recently,several attempts have been made to develop an effective clinical tool for PC screening using a combination of history of new-onset diabetes and several other clinical and biochemical markers.On the contrary,diabetes affects the survival after treatment for PC.We describe this intimate and complex two-way relationship of diabetes and PC in this review by exploring the underlying pathogenesis. | Ayan Roy Jayaprakash Sahoo Sadishkumar Kamalanathan Dukhabandhu Naik Pazhanivel Mohan Raja Kalayarasan | 2021 | World Journal of Gastroenterology2021，27，30： | 3 |
| 4 | Evidence for current diagnostic criteria of diabetes mellitus显示文摘Diabetes mellitus is a non-communicable metabolicderangement afflicting several millions of individuals globally. It is associated with several micro and macro-vascular complications and is also a leading cause of mortality. The unresolved issue is that of definition of the diagnostic threshold for diabetes. The World Health Organization and the American Diabetes Asso-ciation(ADA) have laid down several diagnostic criteria for diagnosing diabetes and prediabetes based on the accumulating body of evidence.This review has attempted to analyse the scientific evidence supporting the justification of these differing criteria. The evidence for diagnosing diabetes is strong, and there is a concordance between the two professional bodies. The controversy arises when describing the normal lower limit of fasting plasma glucose(FPG) with little evidence favouring the reduction of the FPG by the ADA. Several studies have also shown the development of complications specific for diabetes in patients with prediabetes as defined by the current criteria though there is a significant overlap of such prevalence in individuals with normoglycemia. Large multinational longitudinal prospective studies involving subjects without diabetes and retinopathy at baseline will ideally help identify the threshold of glycemic measurements for future development of diabetes and its complications. | Ritesh Kumar Lakshmana Perumal Nandhini Sadishkumar Kamalanathan Jayaprakash Sahoo Muthupillai Vivekanadan | 2016 | World Journal of Diabetes2016，7，17： | 2 |
| 5 | Early detection of hypertension in general practice显示文摘 | Sundaram B kamalanathan AN | 2003 | Arch Dis Child2003，88，4： | 1 |
| 6 | HRSGs for combined cycle power plants 显示文摘 | SUBRAHMANYAM N R1LIARAM S KAMALANATHAN N | 1995 | Heat Recovery Syst CHP1995，15，2： | 1 |
| 7 | Pregnancy in polycystic ovary syndrome显示文摘 | Kamalanathan S Sahoo JP Sathyapalan T | 2013 | Indian J Endocrinol Metab2013，17，1： | 1 |
| 8 | Primary hyperparathyroidism presenting as acute pancreatitis: An institutional experience with review of the literature显示文摘BACKGROUND Acute pancreatitis(AP)presenting as an initial manifestation of primary hyperparathyroidism(PHPT)is uncommon,and its timely diagnosis is crucial in preventing recurrent attacks of pancreatitis.AIM To determine the clinical,biochemical,and radiological profile of PHPT patients presenting as AP.METHODS This is a retrospective observational study,51 consecutive patients admitted with the diagnosis of PHPT during January 2010 and October 2021 at a tertiary care hospital in Puducherry,India was included.The diagnosis of AP was established in the presence of at least two of the three following features:abdominal pain,levels of serum amylase or lipase greater than three times the normal,and characteristic features at abdominal imaging.RESULTS Out of the 51 consecutive patients with PHPT,twelve(23.52%)had pancreatitis[5(9.80%)AP,seven(13.72%)chronic pancreatitis(CP)].PHPT with AP(PHPT-AP)was more common among males with the presentation at a younger age(35.20±16.11 vs 49.23±14.80 years,P=0.05)and lower plasma intact parathyroid hormone(iPTH)levels[125(80.55-178.65)vs 519.80(149-1649.55,P=0.01)]compared to PHPT without pancreatitis(PHPT-NP).The mean serum calcium levels were similar in both PHPT-AP and PHPT-NP groups[(11.66±1.15 mg/dL)vs(12.46±1.71 mg/dL),P=0.32].PHPT-AP also presented with more gastrointestinal symptoms like abdominal pain,nausea,and vomiting with lesser skeletal and renal manifestations as compared to patients with PHPT-NP.CONCLUSION AP can be the only presenting feature of PHPT.Normal or higher serum calcium levels during AP should always draw attention towards endocrine causes like PHPT. | K G Rashmi Sadishkumar Kamalanathan Jayaprakash Sahoo Dukhabandhu Naik Pazhanivel Mohan Biju Pottakkat Sitanshu Sekhar Kar Rajan Palui Ayan Roy | 2022 | World Journal of Gastrointestinal Pharmacology and Therapeutics2022，13，4： | 1 |
| 9 | Age dependence of endogenous galactose formation in Q188R homozygous galactosemic patients显示文摘 | Schadewaldt P Kamalanathan L Hammen HW | 2004 | Mol Genet Metab2004，81，1： | 1 |
| 10 | Pregnancy in polycystic ovary syndrome显示文摘 | Kamalanathan S Sahoo JP Sathyapalan T | 2013 | Indian J Endocrinol Metab2013，17，1： | 1 |
| 11 | Black ad- renal adenoma: distinction from PPNAD 显示文摘 | Kamalanathan S Mahesh DM Mumganandham K | 2012 | BMJ Case Rep2012，，： | 1 |
| 12 | Pregnancy in polycystic ovary syndrome显示文摘 | Kamalanathan S Sahoo JP Sathyapalan T | 2013 | Indian J Endocrinol Metab2013，17，1： | 1 |
| 13 | Beak and feather disease virus and porcine circovirus genomes: intermediates between the geminiviruses and plant circoviruses显示文摘 | F. D. Niagro A. N. Forsthoefel R. P. Lawther L. Kamalanathan B. W. Ritchie K. S. Latimer P. D. Lukert | 1998 | Archives of Virology1998，，9： | 1 |
| 14 | Incretin based therapy and pancreatic cancer:Realising the reality显示文摘Incretin-based therapies like glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors help maintain the glycaemic control in patients with type 2 diabetes mellitus with additional systemic benefits and little risk of hypoglycaemia.These medications are associated with low-grade chronic pancreatitis in animal models inconsistently.The incidence of acute pancreatitis was also reported in some human studies.This inflammation provides fertile ground for developing pancreatic carcinoma(PC).Although the data from clinical trials and population-based studies have established safety regarding PC,the pathophysiological possibility that low-grade chronic pancreatitis leads to PC remains.We review the existing literature and describe the relationship between incretin-based therapies and PC. | Varun Suryadevara Ayan Roy Jayaprakash Sahoo Sadishkumar Kamalanathan Dukhabandhu Naik Pazhanivel Mohan Raja Kalayarasan | 2022 | World Journal of Gastroenterology2022，28，25： | 1 |
| 15 | Beak and feather disease virus and porcine circovirus genomes: intermediates between the geminiviruses and plant circoviruses显示文摘 | F. D. Niagro A. N. Forsthoefel R. P. Lawther L. Kamalanathan B. W. Ritchie K. S. Latimer P. D. Lukert | 1998 | Archives of Virology1998，，9： | 1 |
| 16 | Early detection of hypertension in general practice显示文摘 | Somu S Sundaram B Kamalanathan AN | 2003 | Arch Dis Child2003，88，4： | 1 |
| 17 | ^blalMP and blaVIM mediated carbapenem resistance in Pseudomonas and Acinetobacter species in India 显示文摘 | AMUDHAN M S SEKAR U KAMALANATHAN A | 2012 | J Infect Dev Ctries2012，26，11： | 1 |
| 18 | Complete and curative excision of hypothalamic hamartomas via the orbito - zygomatic approach 显示文摘 | Roopesh Kumar VR1 Madhugiri VS Kamalanathan SK | 2013 | Neurol India2013，61，6： | 1 |
| 19 | Bone mineraldensity and factors influencing it in Asian Indian population withtype 2 diabetes mellitus 显示文摘 | Kamalanathan S Nambiar V Shivane V | 2014 | Indian J Endocrinol Metab2014，18，6： | 1 |
| 20 | Effect of Frey's procedure on islet cell function in patients with chronic calcific pancreatitis显示文摘Background: Frey's procedure involves both drainage and resection of the pancreas in subjects with chronic calcific pancreatitis(CCP). The procedure may affect the pancreatic endocrine function after surgery. The present study was to evaluate the effect of Frey's procedure on both beta and alpha cell function in CCP patients.Methods: Thirty CCP patients who underwent Frey's procedure were included. According to the glycemic status, patients were divided into the diabetes mellitus(DM), prediabetes, and normal glucose tolerance(NGT) groups. Islet cell function was assessed before and 3 months after surgery.Results: At baseline, there was a significant difference in beta cell function among the three groups [NGT group 1.71(1.64–2.07) vs prediabetes group1.50(0.83–1.61) vs DM group 0.33(0.12–0.55), P < 0.0001], but the insulin resistance was not different among them. Post glucose hyperglucagonemia representing alphacell dysfunction during oral glucose tolerance test was present in all of them, but showed no significant difference [NGT group 0.15(0.06–0.31) vs prediabetes group 0.32(0.05–0.70) vs DM group 0.07(0.02–0.18), P = 0.20]. Frey's procedure did not change beta cell function and insulin resistance. However, alphacell dysfunction deteriorated after surgery [0.10(0.03–0.27) vs 0.33(0.09–0.68), P = 0.004].Conclusions: Although Frey's procedure does not affect the beta cell function and insulin resistance in CCP patients, the alpha-cell dysfunction deteriorates after surgery. | Ritesh Kumar Jaya Prakash Sahoo Biju Pottakat Sadishkumar Kamalanathan Pazhanivel Mohan Vikram Kate Sitanshu Sekhar Kar Jayakumar Selviambigapathya | 2018 | Hepatobiliary & Pancreatic Diseases International2018，17，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员